Canaccord Genuity Initiates Coverage On ADMA Biologics with Buy Rating, Announces Price Target of $21

Benzinga Newsdesk www.benzinga.com Neutral 54.4%

Neg 0% Neu 54.4% Pos 0%

Canaccord Genuity analyst Gary Nachman initiates coverage on ADMA Biologics (NASDAQ:ADMA) with a Buy rating and announces Price Target of $21.